series-b
Stage
1
Investors
About
Quanta Therapeutics develops allosteric small molecule inhibitors targeting KRAS mutations such as KRAS G12D and G12V to treat various hard-to-treat cancers by modulating RAS signaling at the cell membrane.
Explore Quanta Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.